Jaguar Health Converts $175K Debt and Buys Out Napo Therapeutics Minority Stake for 2.6M Shares

summarizeSummary

Jaguar Health converted $175K of debt and retired Series Q preferred shares for common stock, and bought out a Napo Therapeutics minority holder for 2.6M shares plus a pre-funded warrant.

check_boxKey Events · Financing and Capital Events · JAGX

• Debt Converted to Equity

  Issued 557,377 shares to Lincoln Alternative Strategies LLC to cancel a $175,016.36 convertible note balance, eliminating that debt obligation.

• Preferred Shares Retired

  Issued 219,435 shares on Sept 11 and 31,847 shares on Sept 14 to Streeterville Capital to cancel 3.2 shares of Series Q Preferred Stock.

• Napo Therapeutics Buyout

  Acquired Joshua Mailman's minority stake in Napo Therapeutics for 535,000 shares plus a pre-funded warrant for 2,077,255 shares at $0.0001 exercise price — 2,612,255 shares total.

• Potential Dilution

  The pre-funded warrant is effectively free to exercise, adding up to 2,077,255 shares of potential dilution on top of the 1,343,659 shares issued in the exchanges.

auto_awesomeAnalysis · JAGX · Life Sciences

Jaguar Health is cleaning up its balance sheet by converting a $175,016 convertible note into 557,377 shares and retiring 3.2 shares of Series Q Preferred Stock for 251,282 shares. More significantly, it acquired the remaining minority interest in Napo Therapeutics from Joshua Mailman for 535,000 shares plus a pre-funded warrant covering 2,077,255 shares — a total of 2,612,255 shares. The warrant carries a nominal $0.0001 exercise price, meaning Mailman can effectively convert it into common stock at almost no cost, adding substantial potential dilution. Against a backdrop of a going-concern warning and only $3.8M in cash as of the last 10-Q, these exchanges reduce debt and preferred obligations but expand the share count at a time when the stock trades near $0.22.